Lloyd Haskell

发表

Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population Continued Anticoagulation with Rivaroxaban for Prevention of Recurrent Symptomatic Venous Thromboembolism in

B. Levitan, F. Laliberté, C. Crivera, 2018 .

Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population

M. Prins, Yongling Xiao, P. Prandoni, 2018 .